Nanologica AB (NICA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanologica AB (NICA) has a cash flow conversion efficiency ratio of -0.064x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.22 Million ≈ $-669.05K USD) by net assets (Skr97.50 Million ≈ $10.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Nanologica AB for the company's overall valuation and market capitalisation.
Nanologica AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Nanologica AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nanologica AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanologica AB ranked by their cash flow conversion efficiency. Explore Nanologica AB (NICA) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pursuit Minerals Ltd
AU:PUR
|
-0.019x |
|
Vesuvius PLC
LSE:VSVS
|
0.057x |
|
ClearOne Inc
NASDAQ:CLRO
|
-2.656x |
|
YY Group Holding Limited Class A Ordinary Shares
NASDAQ:YYGH
|
-0.093x |
|
Geoprima Solusi Tbk PT
JK:GPSO
|
-0.036x |
|
Immolease Trust NV
BR:DIEG
|
N/A |
|
Natuzzi SpA
NYSE:NTZ
|
0.037x |
|
Plasticos Compuestos S.A.
MC:KOM
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Nanologica AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Nanologica AB from 2015 to 2025. View NICA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr22.64 Million ≈ $2.44 Million |
Skr-39.88 Million ≈ $-4.29 Million |
-1.761x | -61.68% |
| 2024-12-31 | Skr74.11 Million ≈ $7.98 Million |
Skr-80.73 Million ≈ $-8.69 Million |
-1.089x | -105.77% |
| 2023-12-31 | Skr-1.90 Million ≈ $-204.26K |
Skr-35.85 Million ≈ $-3.86 Million |
18.887x | +3155.69% |
| 2022-12-31 | Skr73.16 Million ≈ $7.87 Million |
Skr-45.22 Million ≈ $-4.87 Million |
-0.618x | +31.41% |
| 2021-12-31 | Skr51.60 Million ≈ $5.55 Million |
Skr-46.49 Million ≈ $-5.00 Million |
-0.901x | -93.29% |
| 2020-12-31 | Skr92.97 Million ≈ $10.00 Million |
Skr-43.34 Million ≈ $-4.66 Million |
-0.466x | +83.33% |
| 2019-12-31 | Skr4.12 Million ≈ $443.48K |
Skr-11.52 Million ≈ $-1.24 Million |
-2.796x | -466.33% |
| 2018-12-31 | Skr23.71 Million ≈ $2.55 Million |
Skr-11.71 Million ≈ $-1.26 Million |
-0.494x | +95.87% |
| 2017-12-31 | Skr1.94 Million ≈ $208.60K |
Skr-23.19 Million ≈ $-2.50 Million |
-11.965x | -1036.92% |
| 2016-12-31 | Skr22.03 Million ≈ $2.37 Million |
Skr-23.19 Million ≈ $-2.50 Million |
-1.052x | -82.15% |
| 2015-12-31 | Skr24.14 Million ≈ $2.60 Million |
Skr-13.95 Million ≈ $-1.50 Million |
-0.578x | -- |
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more